Overview
- Exact Sciences shareholders will receive $105 per share in cash, valuing the equity at about $21 billion and about $23 billion including roughly $1.8 billion of assumed net debt.
- The companies expect to close in the second quarter of 2026, pending Exact Sciences shareholder and regulatory approvals, after unanimous board sign-offs.
- Exact’s Cologuard and Oncotype DX, along with liquid biopsy and molecular residual disease tests, will be added to Abbott’s diagnostics portfolio.
- Abbott projects Exact Sciences to generate more than $3 billion in 2025 revenue and says combined diagnostics sales will exceed $12 billion annually after closing.
- Exact Sciences shares rose about 17% on the news while Abbott slipped nearly 2%, and CEO Kevin Conroy will serve in an advisory role as the Madison, Wisconsin presence is retained.